North American cost analysis of brand name versus generic drugs for the treatment of glaucoma

被引:6
|
作者
Malvankar-Mehta, Monali S. [1 ,2 ]
Feng, Lucy [3 ]
Hutnik, Cindy M. L. [1 ,4 ]
机构
[1] Univ Western Ontario, Schulich Sch Med & Dent, Dept Ophthalmol, London, ON N6A 4V2, Canada
[2] Univ Western Ontario, Schulich Sch Med & Dent, Dept Epidemiol & Biostat, London, ON N6A 5C1, Canada
[3] Univ Waterloo, Sch Pharm, Kitchener, ON N2G 2B2, Canada
[4] Univ Western Ontario, Schulich Sch Med & Dent, Dept Pathol, London, ON N6A 5C1, Canada
来源
关键词
glaucoma; open-angle; cost analysis; generic drugs; branded drugs; MEDICATION; HEALTH; EFFICACY; SAFETY;
D O I
10.2147/CEOR.S156558
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: According to the World Health Organization, glaucoma is a leading cause of irreversible blindness worldwide. By 2020, 80 million people will be affected by glaucoma in the world, which represents a significant financial burden to society. Glaucoma medications alone make up 38-52% of the total direct cost. The purpose of this research is to conduct a cost-minimization analysis to evaluate brand-name medications versus generic medications for treating glaucoma patients. Methods: The per-bottle cost (in Canadian dollars) of brand-name drugs for glaucoma was obtained from the wholesaler, McKesson Canada, and, for generic drugs, from the Ontario Drug Benefit (ODB) Formulary. Further, a wastage adjustment fee, a pharmacy mark-up, and an ODB dispensing fee ($CAD) was added to the cost of both brand and generic. Previously published frequencies of medication prescription were utilized to calculate the average annual cost for each class of brand and generic. For each medication class and for mono-, bi-, and tri-drug therapy, the cost differential between brands and generics over a six-year period was computed and analyzed from third-party payer perspective. Results: In descending order, the average annual government-funded health care system costs were: combination drugs such as Cosopt (R) ($748.23) were the most expensive, followed by prostaglandin analogs ($246.36), carbonic anhydrase inhibitors (CAIs) ($45.04), alpha-agonist ($30.34), beta-blockers ($29.29), and cholinergic agonists ($16.51). Brand-name mono-drugs are 34% more expensive compared to generics. Brand-generic percentage cost differential for various medication classes over a six-year period was the highest for prostaglandin analogous (44%), followed by beta-blockers (35%), alpha-agonist (31%), cholinergic agonists (22%), combination drugs (10%), and CAIs (1%). Conclusion: Brand-name drugs are relatively more expensive than their generic counter-parts, with variable cost differentials depending on drug class.
引用
收藏
页码:789 / 798
页数:10
相关论文
共 50 条
  • [1] Generic versus brand-name North American topical glaucoma drops
    Mammo, Zaid N.
    Flanagan, John G.
    James, David F.
    Trope, Graham E.
    [J]. CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2012, 47 (01): : 55 - 61
  • [2] Generic versus Brand-Name North American Topical Glaucoma Drops
    Mammo, Z.
    Flanagan, J. G.
    James, D. F.
    Trope, G. E.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [3] GENERIC VERSUS BRAND NAME DRUGS
    不详
    [J]. RHODE ISLAND MEDICAL JOURNAL, 1974, 57 (01): : 26 - 26
  • [4] Brand-Name Versus Generic Drugs
    Manning, Richard
    Smith, Richard
    [J]. HEALTH AFFAIRS, 2011, 30 (10) : 2027 - 2027
  • [5] GENERIC VS BRAND NAME DRUGS FOR THE TREATMENT OF HYPERTENSION
    Dinic, Miriana
    Maillard, Nicolas
    Bouiller, Marc
    Alamartine, Eric
    Mariat, Christophe
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [6] Generic Versus Brand Name Drugs in Psychopharmacology: A Pharmacoeconomic Perspective
    Emanuele, Enzo
    [J]. SOUTHERN MEDICAL JOURNAL, 2011, 104 (10) : 715 - 716
  • [7] Brand Name Versus Generic?
    Aungaroon, Gewalin
    [J]. EPILEPSY CURRENTS, 2023, 23 (03) : 141 - 143
  • [8] BRAND NAME VERSUS GENERIC
    EISENGART, MA
    MELCHINGER, DB
    LIPTON, LC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1964, 271 (05): : 269 - &
  • [9] COST MINIMIZATION ANALYSIS FOR GENERIC AND BRAND NAME ANTIBIOTICS
    Malhan, S.
    Tulunay, F. C.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A114 - A114
  • [10] GENERIC VS BRAND-NAME DRUGS FOR THE TREATMENT OF HYPERTENSION
    Dinic, M.
    Maillard, N.
    Bouiller, M.
    Alamartine, E.
    Mariat, C.
    [J]. JOURNAL OF HYPERTENSION, 2018, 36 : E123 - E123